Find Funding Opportunities

Returning 185 results

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)

PAR
Friday, October 26, 2018
Wednesday, September 15, 2021
U01
PAR-19-039

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-18-NNN). The scope of this FOA encompasses Technical Readiness Level (TRL) 1-3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)

PAR
Friday, October 26, 2018
Wednesday, September 15, 2021
U01
PAR-19-040

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. The mission of the CounterACT Program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scaleable manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)

RFA
Monday, October 22, 2018
Monday, June 28, 2021
U24
RFA-NS-19-006

Funding Opportunity Purpose

This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.

BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)

RFA
Thursday, October 18, 2018
Saturday, October 10, 2020
R01
RFA-MH-19-400

Funding Opportunity Purpose

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, is one of several FOAs aimed at supporting transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. The hope is that efforts supported under this FOA might be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

PAR
Friday, October 5, 2018
Friday, April 16, 2021
U01
PAR-18-951

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional)

PAR
Friday, October 5, 2018
Saturday, December 12, 2020
X02
PAR-18-950

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00)

RFA
Wednesday, October 3, 2018
Workforce Diversity
Friday, April 16, 2021
RFA-NS-19-011

Funding Opportunity Purpose

The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers.

Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)

PA
Wednesday, September 26, 2018
Saturday, January 8, 2022
R01
PA-18-937

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.

Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)

PA
Wednesday, September 26, 2018
Saturday, January 8, 2022
R21
PA-18-939

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.

BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed)

RFA
Friday, September 21, 2018
Saturday, January 25, 2020
R01
RFA-MH-19-148

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) intends to accelerate the integration and use of scalable technologies and tools to enhance and reinvigorate brain cell census research, including the development of technology platforms and/or resources that will enable a swift and comprehensive survey of brain cell types and circuits. Of particular interest are those that will (a) improve technology and resource platforms to remove limitations and bottlenecks in the current pipeline of brain cell census data generation; (b) integrate experimental and computational methods to enhance capabilities of cell census data generation and analysis and to reduce barriers to hypothesis-driven research; (c) generate a substantial amount of spatiotemporal cell census data and/or resources to demonstrate the utility of the improved technology and resource platforms; and (d) conduct comparative studies by using proper criteria to evaluate and benchmark quality of biospecimen, performance of cell census tools/technologies, and effectiveness of computational approaches. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to generate a substantial amount of cell census data using the proposed technologies or via collaboration with the BICCN.

Pages